Page 12 - Polypid Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Artivion (NYSE:AORT – Get Rating) and PolyPid (NASDAQ:PYPD – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Artivion and PolyPid’s top-line revenue, […]

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming...

02.06.2022 - PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) - PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 ...

PolyPid (NASDAQ:PYPD – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. The firm currently has a $5.25 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 4.79% from […]